{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:09:08Z","timestamp":1774505348454,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.peptides.2023.170990","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T02:01:49Z","timestamp":1678154509000},"page":"170990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The angiotensin AT2-receptor agonist compound 21 is an antagonist for the thromboxane TP-receptor \u2013 Implications for preclinical studies and future clinical use"],"prefix":"10.1016","volume":"164","author":[{"given":"Maise H.","family":"Fredgart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Leurgans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stenelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Nybo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bloksgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Lindblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo G.R.","family":"De Mey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U. Muscha","family":"Steckelings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.peptides.2023.170990_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharm. Rev."},{"issue":"4","key":"10.1016\/j.peptides.2023.170990_bib2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/pharmrev.120.000281","article-title":"The angiotensin AT2 receptor: from a binding site to a novel therapeutic target","volume":"74","author":"Steckelings","year":"2022","journal-title":"Pharm. Rev."},{"issue":"24","key":"10.1016\/j.peptides.2023.170990_bib3","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","article-title":"Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist","volume":"47","author":"Wan","year":"2004","journal-title":"J. Med Chem."},{"issue":"1 Pt 2","key":"10.1016\/j.peptides.2023.170990_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/01.HYP.31.1.349","article-title":"AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism","volume":"31","author":"Gohlke","year":"1998","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.peptides.2023.170990_bib5","first-page":"958","article-title":"Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor","volume":"48","author":"Yayama","year":"2006","journal-title":"Hypertens. Dallas Tex. 1979"},{"issue":"7","key":"10.1016\/j.peptides.2023.170990_bib6","first-page":"777","article-title":"Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase","volume":"132","author":"Peluso","year":"2018","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"issue":"3","key":"10.1016\/j.peptides.2023.170990_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1476-5381.2009.00575.x","article-title":"Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats","volume":"159","author":"Bosnyak","year":"2010","journal-title":"Br. J. Pharm."},{"issue":"19","key":"10.1016\/j.peptides.2023.170990_bib8","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1161\/01.CIR.0000128696.12245.57","article-title":"Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries","volume":"109","author":"Batenburg","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.peptides.2023.170990_bib9","first-page":"824","article-title":"Role of angiotensin type 2 receptors in vasodilation of resistance and capacitance vessels","volume":"48","author":"Carey","year":"2006","journal-title":"Hypertens. Dallas Tex. 1979"},{"issue":"4","key":"10.1016\/j.peptides.2023.170990_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095762","article-title":"Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats","volume":"9","author":"McCarthy","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.peptides.2023.170990_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/01.HYP.0000253968.95136.b8","article-title":"Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients","volume":"49","author":"Savoia","year":"2007","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.peptides.2023.170990_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/HYPERTENSIONAHA.112.196022","article-title":"Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism","volume":"60","author":"Verdonk","year":"2012","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.peptides.2023.170990_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/en.2017-00585","article-title":"Direct activation of angiotensin II type 2 receptors enhances muscle microvascular perfusion, oxygenation, and insulin delivery in male rats","volume":"159","author":"Yan","year":"2018","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.peptides.2023.170990_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/med.21449","article-title":"Small-molecule AT2 receptor agonists","volume":"38","author":"Hallberg","year":"2018","journal-title":"Med Res Rev."},{"issue":"3","key":"10.1016\/j.peptides.2023.170990_bib15","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3390\/molecules20033868","article-title":"Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors","volume":"20","author":"Kellici","year":"2015","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.peptides.2023.170990_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00005344-200307000-00007","article-title":"Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins","volume":"42","author":"Hakim","year":"2003","journal-title":"J. Cardiovasc Pharm."},{"issue":"2","key":"10.1016\/j.peptides.2023.170990_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00005344-199808000-00005","article-title":"Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats","volume":"32","author":"Li","year":"1998","journal-title":"J. Cardiovasc Pharm."},{"issue":"1","key":"10.1016\/j.peptides.2023.170990_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)35282-6","article-title":"Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation","volume":"292","author":"Li","year":"2000","journal-title":"J. Pharm. Exp. Ther."},{"issue":"6551","key":"10.1016\/j.peptides.2023.170990_bib19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/377744a0","article-title":"Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice","volume":"377","author":"Hein","year":"1995","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.peptides.2023.170990_bib20","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13717","article-title":"Deletion of endothelial arginase 1 does not improve vasomotor function in diabetic mice","volume":"6","author":"Chennupati","year":"2018","journal-title":"Physiol. Rep."},{"issue":"4","key":"10.1016\/j.peptides.2023.170990_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1476-5381.2009.00480.x","article-title":"Bimolecular fluorescence complementation: lighting up seven transmembrane domain receptor signalling networks","volume":"159","author":"Rose","year":"2010","journal-title":"Br. J. Pharm."},{"issue":"2","key":"10.1016\/j.peptides.2023.170990_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1527-3466.2004.tb00132.x","article-title":"Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor","volume":"22","author":"Ishizuka","year":"2004","journal-title":"Cardiovasc Drug Rev."},{"issue":"2\u20133","key":"10.1016\/j.peptides.2023.170990_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(89)90106-4","article-title":"Antagonistic actions of S-145 on vascular and platelet thromboxane A2 receptors","volume":"171","author":"Mihara","year":"1989","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.peptides.2023.170990_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12079-020-00585-0","article-title":"A review of prostanoid receptors: expression, characterization, regulation, and mechanism of action","volume":"15","author":"Biringer","year":"2021","journal-title":"J. Cell Commun. Signal"},{"issue":"5","key":"10.1016\/j.peptides.2023.170990_bib25","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1074\/jbc.274.5.2645","article-title":"Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets","volume":"274","author":"Habib","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2023.170990_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/01.hjh.0000523257.57873.95","article-title":"[PP.02.17] Successful completion of a phase I, randomized, double-Blind, placebo controlled, single ascending dose trial for the first in class angiotensin AT2-receptor agonist compound 21","volume":"35","author":"Steckelings","year":"2017","journal-title":"J. Hypertens."},{"key":"10.1016\/j.peptides.2023.170990_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101152","article-title":"Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial","volume":"41","author":"Tornling","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978123000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978123000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:34:12Z","timestamp":1759311252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978123000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"alternative-id":["S0196978123000529"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2023.170990","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The angiotensin AT2-receptor agonist compound 21 is an antagonist for the thromboxane TP-receptor \u2013 Implications for preclinical studies and future clinical use","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2023.170990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"170990"}}